News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
685,568 Results
Type
Article (39049)
Company Profile (279)
Press Release (646240)
Section
Business (203865)
Career Advice (1990)
Deals (35365)
Drug Delivery (85)
Drug Development (80799)
Employer Resources (168)
FDA (16086)
Job Trends (14804)
News (344544)
Policy (32436)
Tag
Academia (2530)
Alliances (49086)
Alzheimer's disease (1228)
Approvals (16018)
Artificial intelligence (130)
Bankruptcy (352)
Best Places to Work (11534)
Biotechnology (200)
Breast cancer (120)
Cancer (1081)
Cardiovascular disease (97)
Career advice (1660)
Cell therapy (232)
Clinical research (64240)
Collaboration (387)
Compensation (197)
COVID-19 (2530)
C-suite (94)
Data (1119)
Diabetes (152)
Diagnostics (6138)
Earnings (84817)
Employer resources (146)
Events (109470)
Executive appointments (310)
FDA (16621)
Funding (349)
Gene therapy (177)
GLP-1 (575)
Government (4324)
Healthcare (18668)
Infectious disease (2615)
Inflammatory bowel disease (106)
Interviews (308)
IPO (16297)
Job creations (3623)
Job search strategy (1417)
Layoffs (412)
Legal (7853)
Lung cancer (170)
Manufacturing (176)
Medical device (13174)
Medtech (13179)
Mergers & acquisitions (19143)
Metabolic disorders (401)
Neuroscience (1503)
NextGen Class of 2024 (6499)
Non-profit (4464)
Northern California (1476)
Obesity (231)
Opinion (179)
Patents (102)
People (56269)
Phase I (19951)
Phase II (28299)
Phase III (21095)
Pipeline (455)
Postmarket research (2553)
Preclinical (8492)
Radiopharmaceuticals (236)
Rare diseases (218)
Real estate (5890)
Regulatory (21517)
Research institute (2308)
Resumes & cover letters (349)
Southern California (1298)
Startups (3562)
United States (13445)
Vaccines (548)
Weight loss (167)
Date
Today (129)
Last 7 days (802)
Last 30 days (3814)
Last 365 days (35630)
2024 (32674)
2023 (40075)
2022 (51173)
2021 (55712)
2020 (54087)
2019 (46541)
2018 (35019)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (192)
Asia (37118)
Australia (6057)
California (3318)
Canada (1286)
China (247)
Colorado (144)
Connecticut (152)
Europe (79501)
Florida (458)
Georgia (116)
Illinois (341)
Indiana (196)
Kansas (96)
Maryland (575)
Massachusetts (2602)
Michigan (157)
Minnesota (272)
New Jersey (952)
New York (957)
North Carolina (701)
Northern California (1476)
Ohio (139)
Pennsylvania (843)
South America (1091)
Southern California (1298)
Texas (461)
Utah (90)
Washington State (360)
685,568 Results for "systimmune inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
SystImmune, Inc. Announces Transition of Chief Medical Officer
SystImmune, Inc., a pioneering clinical-stage biopharmaceutical company focused on developing novel therapeutic bi-specific, multi-specific antibodies, and antibody-drug conjugates for the treatment of cancer, announced the appointment of Dr. Jonathan Cheng as Chief Medical Officer.
May 23, 2024
·
2 min read
Press Releases
SystImmune, Inc. Announces FDA Clearance of IND Application for BL-M17D1 in Advanced Solid Tumors
November 8, 2024
·
3 min read
Business
SystImmune, Inc. Appoints Dr. Jie D’Elia as Chief Executive Officer
SystImmune, Inc. today announced the appointment of Jie D’Elia, Ph.D., MBA, as its new Chief Executive Officer.
April 22, 2024
·
2 min read
Press Releases
SystImmune, Inc. Announces FDA Clearance of IND Application for BL-M11D1 in Relapsed/Refractory Acute Myeloid Leukemia
October 14, 2024
·
3 min read
Press Releases
SystImmune, Inc. to Present New BL-B01D1 Data in Urothelial, Biliary Tract, and Esophageal Squamous Cell Carcinoma at ESMO Congress 2024
September 9, 2024
·
5 min read
BioForest
SystImmune, Inc. to Present New Oncology Pipeline Data at ESMO Congress 2023
SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced the presentation of pivotal data from its oncology portfolio at the European Society for Medical Oncology (ESMO) Congress 2023.
October 20, 2023
·
5 min read
Business
BMS Inks Potential $8.4B Deal for SystImmune’s ADC for Lung, Breast Cancer
Bristol Myers Squibb has bought the rights to develop and commercialize SystImmune’s potentially first-in-class, bi-specific antibody-drug conjugate for lung and breast cancer as well as other solid tumors.
December 12, 2023
·
2 min read
·
Tristan Manalac
BioForest
SystImmune, Inc. Announces the Presentation of Breast Cancer Clinical Trial Results at the 2024 San Antonio Breast Cancer Conference and US Clinical Trial Developments
SystImmune, Inc (SystImmune), a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) authorized the company to proceed with the planned clinical study of the HER2-specific HIRE platform ADC, BL-M07D1, in the Investigational New Drug (IND) application on November 28, 2023.
December 5, 2023
·
7 min read
Business
SystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1
SystImmune, a clinical-stage biopharmaceutical company, and Bristol Myers Squibb (NYSE: BMY) today announced an exclusive license and collaboration agreement for SystImmune’s BL-B01D1, a potentially first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC).
December 11, 2023
·
8 min read
BioForest
SystImmune, Inc. to Present New Data from Oncology Programs at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2023
Systimmune, Inc. announced that it will present clinical data from its lead programs at the ASCO Annual Meeting 2023 in Chicago in June.
May 1, 2023
·
7 min read
1 of 68,557
Next
